Intratumoural tigilanol tiglate in the multicentre treatment of equine sarcoids and cutaneous melanomas.

ABSTRACT:

Background

Intralesional chemotherapeutic administration represents an important treatment option for equine cutaneous neoplasia. Tigilanol-tiglate (TT), a novel molecule extracted from Fontainea picrosperma, an Australian rainforest plant, is registered for intratumoural treatment of canine MCT, leading to rapid oncosis and tumour slough. Evidence from horses is limited but suggests that efficacy may be similar.

Objectives

To evaluate the response to intratumoural TT treatment in horses with sarcoids (fibroblastic/nodular) and cutaneous melanomas.

Study design

Two noncontrolled prospective multicentre clinical trials, one for each of sarcoids and melanomas.

Methods

Cases were enrolled across multiple sites and treated by the same site-specific clinician with i

SUBMITTER: Labens R 

PROVIDER: S-EPMC12699102 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature